(Date:12/15/2009)... , - ... the Ability of,Cardiopoietic Cells to Restore Cardiac Function ... leading Belgian biotechnology company specialising,in cell-based therapies for ... has completed, two months ahead of schedule,enrolment in ... trial of C-Cure, a,unique stem cell therapy for ...
(Date:12/14/2009)... Joins with State Biotech Leaders to Develop ... and Development while Boosting Rhode Island,s Growing ... PROVIDENCE, R.I., Dec. 14 Several ... research, medicine and biotechnology gathered today at ... the importance of medical innovation in Rhode ...
(Date:12/14/2009)... 14 Decision Resources, one of the ... and healthcare issues, finds that, owing to the ... drug market will increase more than sevenfold from ... 2018 in the United States, France, Germany, Italy, ... new Pharmacor report entitled Atrial Fibrillation ...
(Date:12/11/2009)... Therapeutics, Inc., a biopharmaceutical company focused on improving ... cardiovascular and muscle disease, today announced the publication ... crucial role in the progression of amyotrophic lateral ... neuromuscular synaptic regeneration in mice. The findings, ... journal Science , reveal miR-206 as a ...
Breaking Biology Technology:Cardio3 BioSciences Completes Patient Enrolment in First Stage of Pivotal Trial of C-Cure(R) in Heart Failure 2Cardio3 BioSciences Completes Patient Enrolment in First Stage of Pivotal Trial of C-Cure(R) in Heart Failure 3Former Congressman Dick Gephardt Brings National Spotlight to Rhode Island with 'Best and Brightest Forum on Medical Innovation' 2Former Congressman Dick Gephardt Brings National Spotlight to Rhode Island with 'Best and Brightest Forum on Medical Innovation' 3Former Congressman Dick Gephardt Brings National Spotlight to Rhode Island with 'Best and Brightest Forum on Medical Innovation' 4The Atrial Fibrillation Drug Market Will Increase More Than Sevenfold, from $790 Million in 2008 to $6.1 Billion in 2018 2miRagen announces discovery of key microRNA implicated in Lou Gehrig's disease 2(Date:12/15/2009)... -- Vivakor, Inc. (OTC Bulletin Board: VIVK) ... strong performance in 2009. Vivakor is a ... divisional spokes developing multiple products and technologies ... is anchored to the concept of licensing ... R&D efforts target commercialization and product-specific exit ...
(Date:12/15/2009)... -- Rib-X Pharmaceuticals, Inc., a company focused on ... for the treatment of serious multi-drug-resistant infections announced ... agreement with Massachusetts General Hospital (MGH). ... Dr. David Hooper of MGH will evaluate Rib-X,s ... to determine resistance development and to validate the ...
(Date:12/15/2009)... Dec. 15 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. ... in China, announced today,that Weidong Yin, Chairman, ... Central,Television (CCTV) to be one of 18 ... CCTV,s Economic Man-of-the-Year is ... sometimes referred to as the "Oscar Award ...
Breaking Medicine Technology:Vivakor Divisions Continue to Demonstrate Independent Growth 2Rib-X Pharmaceuticals Enters into Collaborative Agreement on Delafloxacin with Massachusetts General Hospital 2Rib-X Pharmaceuticals Enters into Collaborative Agreement on Delafloxacin with Massachusetts General Hospital 3Sinovac's CEO Weidong Yin Nominated for China Central Television's Prestigious Economic Man-of-the-Year Award 2Sinovac's CEO Weidong Yin Nominated for China Central Television's Prestigious Economic Man-of-the-Year Award 3The Law Firm of Kelley 26 Murphy of Philadelphia Blue Bell and Harrisburg has Filed a Law Suit in the United States District Court for the Eastern D 56730 1The Law Firm of Kelley 26 Murphy of Philadelphia Blue Bell and Harrisburg has Filed a Law Suit in the United States District Court for the Eastern D 56730 2Innovative Program Educates Hopeful Parents on Third Party Reproduction 56727 1Innovative Program Educates Hopeful Parents on Third Party Reproduction 56727 2Innovative Program Educates Hopeful Parents on Third Party Reproduction 56727 3Sambazon Announces Scientific Advisory Board 56722 1Sambazon Announces Scientific Advisory Board 56722 2Sambazon Announces Scientific Advisory Board 56722 3